Compare Novartis AG (NVS) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Financial Select Sector SPDR Fund — how do they compare? Novartis AG trades at $143.11 (market cap $268.57B), while Financial Select Sector SPDR Fund trades at $54.23 (market cap $50.06B). The key difference: Novartis AG is far larger — about 5.4× Financial Select Sector SPDR Fund's market cap, and Novartis AG pays a 3.31% dividend while Financial Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Financial Select Sector SPDR Fund for 104 Days on average.
| NVS | XLF | |
|---|---|---|
Market Cap | $268.57B | $50.06B |
Volume | 1,532,573 | 47,464,120 |
Sector | Health | — |
52-Week High | $168.62 | $58.55 |
52-Week Low | $121.80 | $47.80 |
Typical Hold Time | 82 Days | 104 Days |
Enterprise Value | $309.89B | — |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
XLF trades at $53.75, down 0.48% with bearish technical signals from moving averages. The financial sector faces headwinds as bank stocks lag the S&P 500 by the widest margin since 1990 despite rising profits. Recent Fed stress test changes and interest rate hikes create a mixed environment for financial institutions, with higher rates potentially benefiting some sector components while increasing borrowing costs.
The ETF's concentrated exposure to 76 large-cap financial firms positions it for potential gains from rising rates, though sector underperformance and regulatory uncertainty present near-term challenges. Fund managers increased financial allocations in Q2 2026, suggesting institutional confidence in the sector's rate sensitivity advantages over tech stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
